USPTO Examiner AL AWADI DANAH J - Art Unit 1615

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18437420EXTENDED RELEASE COMPOSITIONS COMPRISING PYRIDOSTIGMINEFebruary 2024September 2024Allow800NoNo
18386399ETHYL 2-[9-(2-HYDROXYQUINOLIN-3-YL)-1,8-DIOXO-3,4,9,10-TETRAHYDROACRIDINE-10-YL]-ACETATE AS AN ANTIMICROBIAL COMPOUNDNovember 2023March 2024Allow410NoNo
184968214,5-BIS(4-METHOXYPHENYL)-1-HEXYL-2-(4-NITROPHENYL)-1H-IMIDAZOLE AS AN ANTIMICROBIAL COMPOUNDOctober 2023February 2024Allow410NoNo
184930722-(BENZO[D]OXAZOL-2-YL)-N'-(PICOLINOYLOXY)ACETIMIDAMIDE AS AN ANTIMICROBIAL COMPOUNDOctober 2023January 2024Allow300NoNo
183814549-(2-HYDROXYPHENYL)-10-[3-(DIMETHYLAMINO)PROPYL]-3,4,6,7,9,10- HEXAHYDROACRIDINE-1,8(2H,5H)-DIONE AS AN ANTIMICROBIAL COMPOUNDOctober 2023January 2024Allow300NoNo
18466404COSMETIC PRODUCTS INCLUDING BIS-CARBOXY SILICONE POLYMER COMPONENTSeptember 2023April 2025Abandon1920NoNo
18460941Ready-To-Use Potassium Phosphates In Sodium Chloride SolutionsSeptember 2023December 2023Allow300NoNo
18360514DRY POWDER COMPOSITIONS OF TREPROSTINIL PRODRUGS AND METHODS OF USE THEREOFJuly 2023September 2024Allow1410NoNo
18329268DRUG DELIVERY SYSTEM COMPRISING A NON-STEROIDAL ANTI-INFLAMMATORY (NSAID) AND A PROGESTOGENIC COMPOUND AND METHODS FOR MANUFACTURINGJune 2023November 2024Abandon1810NoNo
18322065DERMAL SKIN PROTECTANT AND CARRIERMay 2023May 2025Allow2420YesNo
18315605Implantable Device for Sustained Release of a Macromolecular Drug CompoundMay 2023January 2024Allow800NoNo
18136916EXTENDED RELEASE COMPOSITIONS COMPRISING PYRIDOSTIGMINEApril 2023October 2023Allow510NoNo
18191874AQUEOUS COSMETICMarch 2023April 2024Allow1311NoNo
18121679NUTRACEUTICAL COMPOSITIONS AND METHODS FOR DIETARY ALLEVIATION OF POLYCYSTIC OVARY SYNDROMEMarch 2023October 2023Allow721YesNo
18179777COMPOSITIONS COMPRISING SILK FIBROIN PARTICLES AND USES THEREOFMarch 2023August 2024Allow1720NoNo
18168958PHARMACEUTICAL COMPOSITION COMPRISING EICOSAPENTAENOIC ACID AND NICOTINIC ACID AND METHODS OF USING SAMEFebruary 2023October 2024Abandon2011NoNo
18097097METHOD FOR PRODUCING POWDER LEADS AND PRODUCTS PRODUCED THEREWITHJanuary 2023May 2024Allow1611NoNo
18148860INJECTABLE PREPARATIONDecember 2022February 2024Allow1410NoNo
18070186ANTIMICROBIAL COMPLEXESNovember 2022January 2024Abandon1401NoNo
17981080SENSITIZING COMPOSITION USING ELECTROMAGNETIC WAVES FOR THERMAL THERAPY OF CANCERS, AND CANCER THERAPY USING SAMENovember 2022May 2023Allow700NoNo
17950638NOVEL CERIUM OXIDE NANOCOMPLEX AND A COMPOSITION FOR PREVENTING OR TREATING CEREBRAL INFARCTION COMPRISING THE SAMESeptember 2022April 2024Abandon1910NoNo
17945054Vitamins and Alpha Keto Acid Compositions for Use in a Treatment Program for Chronic Kidney Disease PatientsSeptember 2022August 2024Allow2320YesNo
17945043Vitamins and Alpha Keto Acid Compositions for Use in a Treatment Program for Chronic Kidney Disease PatientsSeptember 2022May 2024Allow2010YesNo
17893991DRY POWDER COMPOSITIONS OF TREPROSTINIL PRODRUGS AND METHODS OF USE THEREOFAugust 2022May 2023Allow900NoNo
17881991DOUBLE-STRUCTURED STICK COSMETIC AND MANUFACTURING METHOD THEREOFAugust 2022January 2024Allow1811NoNo
17876348DOSAGE FORM COATING COMPOSITION AND METHOD OF MAKING AND USING THE SAMEJuly 2022May 2025Abandon3430NoYes
17842691Implantable Pharmaceutical Composition Prepared From Components Consisting of Calcium Sulfate Alpha-Hemihydrate, Vancomycin and TobramycinJune 2022March 2024Abandon2101NoNo
17726312Clear Nail Top Coat Compositions And Methods Of MakingApril 2022May 2025Abandon3610NoNo
17769678Clear Nail Top Coat Compositions And Methods Of MakingApril 2022June 2025Abandon3810NoNo
17711122STORAGE STABLE SINCALIDE FORMULATIONSApril 2022January 2023Allow910NoNo
17765196PROTOPANAXATRIOL (PPT)-TYPE COMPOUNDS AS ACTIVE INGREDIENTS IN INSECTICIDE PRODUCTSMarch 2022March 2025Abandon3601NoNo
17701004PHARMACEUTICAL COMPOSITIONS COMPRISING AFATINIBMarch 2022September 2023Allow1810NoNo
17642589PROCESS FOR PRODUCING A PHARMACEUTICAL FORMULATION COMPRISING CRYSTALLINE AND AMORPHOUS FRACTIONS OF AN ACTIVE SUBSTANCEMarch 2022December 2024Abandon3301NoNo
17683840METHOD FOR PRODUCING WEARABLE COATINGMarch 2022May 2023Allow1400NoNo
17652559SELF-THERAPEUTIC NANOPARTICLE FOR ENHANCED TOPICAL DELIVERY TO SKIN KERATINOCYTES AND TREATING SKIN INFLAMMATIONFebruary 2022May 2025Allow3841NoNo
17637841SOLID COSMETICFebruary 2022June 2025Allow4020NoNo
17636732METHOD FOR PRODUCING A BIOACTIVE COMPONENT-CONTAINING NANO-COMPOSITE, AND A MONTMORILLONITE-BASED, BIOACTIVE COMPONENT-CONTAINING NANO-COMPOSITEFebruary 2022May 2025Allow3911NoNo
17636661NO SCENT NO BITEFebruary 2022April 2025Abandon3801NoNo
17633226NOVEL COMPOUNDS FOR SKIN LIGHTENINGFebruary 2022March 2025Abandon3710NoNo
17629760MEDICATION COATED WITH HEMP OR OTHER CANNABINOIDJanuary 2022April 2025Abandon3811NoNo
17627493CHEWING GUM COMPOSITIONS FOR THE TREATMENT OF MENSTRUAL PAINJanuary 2022April 2025Abandon3910NoNo
17646794OIL-DISPERSED COMPOSITION AND COSMETICS FOR LIP CARE USING THE SAMEJanuary 2022November 2023Allow2321NoNo
17566015METHODS OF TREATMENT USING ULTRASMALL NANOPARTICLES TO INDUCE CELL DEATH OF NUTRIENT-DEPRIVED CANCER CELLS VIA FERROPTOSISDecember 2021November 2023Allow2210NoNo
17557105LONG WEAR LIQUID ANHYDROUS COMPOSITIONDecember 2021March 2024Allow2611NoNo
17553648DEODORANT COMPOSITIONSDecember 2021January 2025Abandon3710NoNo
17550117EXTENDED RELEASE COMPOSITIONS COMPRISING PYRIDOSTIGMINEDecember 2021January 2023Allow1321YesNo
17549495ANTICANCER COMPOSITIONSDecember 2021July 2024Abandon3120NoNo
17618256DEODORANT COMPOSITIONSDecember 2021January 2025Abandon3810NoNo
17526266SUGAR-FREE LIP SCRUB COMPOSITIONS AND USES THEREOFNovember 2021October 2023Abandon2320YesNo
17513276METHODS OF INCREASING MAGNESIUM BIOAVAILABILITY AND ABSORPTIONOctober 2021September 2023Allow2211NoNo
17507369PHARMACEUTICAL FORMULATIONS CONTAINING GABOXADOL FOR THERAPEUTIC TREATMENTOctober 2021May 2024Abandon3111NoNo
17502181DRUG DELIVERY CARRIER INCLUDING PLGA AND BETA-CYCLODEXTRIN CONTAINING DRUGOctober 2021January 2024Abandon2711NoNo
17499001Ready-To-Use Potassium Phosphates In Sodium Chloride SolutionsOctober 2021September 2023Allow2300NoNo
17490797METHOD FOR TREATING MYOPIA AND APPLICATION IN PREPARATION OF MEDICAMENTSeptember 2021May 2024Abandon3121YesNo
17484725DRUG DELIVERY SYSTEM FOR TREATMENT OF CANCERSeptember 2021June 2025Allow4420NoNo
17480892HAIR CONDITIONING COMPOSITIONSeptember 2021April 2024Abandon3020NoNo
17439829COMPOSITIONS COMPRISING CURCUMIN AND COENZYME Q10September 2021August 2024Abandon3511NoNo
17475741LAVAGE TECHNIQUES AND VIRUCIDAL COMPOSITIONS COMPRISING HYPOCHLOROUS SOLUTIONSSeptember 2021March 2025Abandon4230NoNo
17473826Dental Local Anesthetic SolutionSeptember 2021February 2023Abandon1721NoNo
17468401ANTIPERSPIRANT AND DEODORANT FORMULATION AND METHOD OF PROCESSING THE SAMESeptember 2021June 2023Abandon2111NoNo
17462404EYELASH COATING COMPOSITIONS FOR FALSE EYELASHESAugust 2021January 2024Abandon2921NoNo
17397444STORAGE STABLE SINCALIDE FORMULATIONSAugust 2021January 2022Allow500YesNo
17444469INJECTABLE PREPARATIONAugust 2021October 2022Allow1400YesNo
17387420COSMETIC COMPOSITIONJuly 2021August 2024Abandon3721NoNo
17376733PHARMACEUTICAL COMPOSITION COMPRISING EICOSAPENTAENOIC ACID AND NICOTINIC ACID AND METHODS OF USING SAMEJuly 2021February 2023Abandon1910NoNo
17366863NON-DIGESTIBLE CAPSULES FOR THE DELIVERY OF FLUID ABSORBING MATERIALSJuly 2021March 2025Abandon4540YesYes
17345462STARCH-BASED RELEASE MODIFYING EXCIPIENTS AND PHARMACEUTICAL COMPOSITIONS DERIVED THEREFROMJune 2021August 2022Allow1400NoNo
17303915DERMAL SKIN PROTECTANT AND CARRIERJune 2021February 2023Allow2010NoNo
17342368SHEAR-THINNING SELF-HEALING NETWORKSJune 2021August 2022Allow1410NoNo
17334670Formulation for and Method of Using an Herbal Tea for the Treatment of Urinary Tract InfectionsMay 2021October 2023Abandon2801NoNo
17326327OILY STICK-SHAPED COSMETICMay 2021November 2022Allow1810NoNo
17319496TETRAHYDROCURCUMINOID-METAL COMPLEXES, MANUFACTURING METHODS THEREOF, AND USES THEREOFMay 2021August 2024Abandon3921NoNo
17316208DRUG-DEVICE UNIT CONTAINING QUINAGOLIDEMay 2021February 2024Abandon3421NoNo
17292238Pharmaceutical Composition For Preventing Or Treating Obesity, Containing CYCLO(HIS-PRO) As Active IngredientMay 2021December 2024Abandon4310NoNo
17290360MOSQUITO ATTRACTANT FORMULATIONS AND USES THEREOFApril 2021April 2025Allow4821YesNo
17285234THERAPEUTIC OR PROPHYLACTIC AGENT FOR NOCTURNAL POLYURIAApril 2021November 2024Abandon4320NoNo
17282999GEL, IN PARTICULAR FOR USE IN A WOUND TREATMENT AGENTApril 2021November 2024Abandon4410NoNo
17219479SENSITIZING COMPOSITION USING ELECTROMAGNETIC WAVES FOR THERMAL THERAPY OF CANCERS, AND CANCER THERAPY USING SAMEMarch 2021February 2023Abandon2210NoNo
17279972OIL-IN-WATER TYPE SUNSCREEN COSMETICMarch 2021December 2023Allow3201NoNo
17212397Volume Boosting Molding Hair Coloring Creme FormulationMarch 2021January 2023Abandon2210NoNo
17278756PERACETIC ACID STABILIZED COMPOSITIONS WITH STABLE LININGMarch 2021March 2024Allow3600NoNo
17200766COMPOSITIONS COMPRISING SILK FIBROIN PARTICLES AND USES THEREOFMarch 2021November 2022Allow2131NoNo
17200764COMPOSITIONS COMPRISING SILK FIBROIN PARTICLES AND USES THEREOFMarch 2021November 2022Allow2131NoNo
17271869MATERIALS CONTAINING COPPER AND THEIR USE IN BENEFICIAL BODY HEALTHFebruary 2021May 2025Abandon5121NoNo
17271790COMPOSITION FOR IMPROVING SKIN TRANSPARENCY AND REDUCING DULLNESSFebruary 2021September 2023Allow3000YesNo
17271146IMPROVED CANNABINOID BIOAVAILABILITYFebruary 2021March 2024Abandon3601NoNo
17271152ORAL FORMULATIONS OF LAVENDER AND CANNABINOIDSFebruary 2021March 2024Abandon3601NoNo
17269590LUBRICATION METHODFebruary 2021October 2023Allow3200NoNo
17269311Supplement for animal feed for sucking pigsFebruary 2021September 2024Abandon4320NoNo
17267325COSMETIC PRODUCTFebruary 2021August 2024Allow4211NoNo
17264683WATER-CONTAINING LIPSTICK AND PREPARATION METHOD THEREFORJanuary 2021December 2022Abandon2321NoNo
17159960LIP COMPOSITIONJanuary 2021October 2024Allow4540NoNo
17261929DERMATOLOGICAL COMPOSITIONS FOR PROVIDING NUTRIENTS TO SKIN AND METHODS THEREOFJanuary 2021May 2025Abandon5151NoYes
17139370THERAPEUTIC AGENT FOR HYPERPHOSPHATEMIA AND PARTICLESDecember 2020September 2024Abandon4540YesNo
17124668Ready to Use Injectable formulations of Melphalan and processes for preparation thereofDecember 2020August 2023Allow3231YesNo
17120547Solid honey product and method of producing the sameDecember 2020December 2023Abandon3620NoNo
17117967PHARMACEUTICAL COMPOSITION COMPRISING AMNIOTIC FLUID STEM CELL SPHEROID AND THE USE THEREOF IN TREATMENT OF URINARY INCONTINENCEDecember 2020February 2023Allow2621NoNo
17110982Glue-free Adhesive EyeleashesDecember 2020April 2022Abandon1610NoNo
16956047COSMETIC COMPOSITION COMPRISING A CAESALPINIA SPINOSA EXTRACT, A KAPPAPHYCUS ALVAREZII EXTRACT, AT LEAST ONE PREBIOTIC AND A PROBIOTICDecember 2020March 2025Abandon5741NoNo
17108939INJECTABLE PREPARATIONDecember 2020June 2021Allow710YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner AL-AWADI, DANAH J.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
21
Examiner Affirmed
15
(71.4%)
Examiner Reversed
6
(28.6%)
Reversal Percentile
42.9%
Lower than average

What This Means

With a 28.6% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
82
Allowed After Appeal Filing
17
(20.7%)
Not Allowed After Appeal Filing
65
(79.3%)
Filing Benefit Percentile
24.0%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 20.7% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner AL-AWADI, DANAH J - Prosecution Strategy Guide

Executive Summary

Examiner AL-AWADI, DANAH J works in Art Unit 1615 and has examined 822 patent applications in our dataset. With an allowance rate of 53.3%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 33 months.

Allowance Patterns

Examiner AL-AWADI, DANAH J's allowance rate of 53.3% places them in the 9% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by AL-AWADI, DANAH J receive 2.56 office actions before reaching final disposition. This places the examiner in the 87% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by AL-AWADI, DANAH J is 33 months. This places the examiner in the 26% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +15.6% benefit to allowance rate for applications examined by AL-AWADI, DANAH J. This interview benefit is in the 59% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 18.8% of applications are subsequently allowed. This success rate is in the 11% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 20.6% of cases where such amendments are filed. This entry rate is in the 18% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 84.2% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 63% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 61.1% of appeals filed. This is in the 33% percentile among all examiners. Of these withdrawals, 57.6% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.

Petition Practice

When applicants file petitions regarding this examiner's actions, 57.3% are granted (fully or in part). This grant rate is in the 73% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 2.7% of allowed cases (in the 81% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.5% of allowed cases (in the 49% percentile). This examiner issues Quayle actions less often than average. Allowances may come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Expect multiple rounds of prosecution: This examiner issues more office actions than average. Address potential issues proactively in your initial response and consider requesting an interview early in prosecution.
  • Plan for RCE after final rejection: This examiner rarely enters after-final amendments. Budget for an RCE in your prosecution strategy if you receive a final rejection.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.